Large gap with delayed quotes
Analysis date: 14.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 14.04.2026.
Interest
Very strong
Very strong
Four stars since 14.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 14.04.2026 at a price of 180.80.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 14.04.2026.
4wk Rel Perf
9.04%
9.04%
The four-week dividend-adjusted overperformance versus STOXX600 is 9.04%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 30.01.2026.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.21%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.38%.
Mkt Cap in $bn
19.78
19.78
With a market capitalization >$8bn, SARTORIUS STEDIM BIOTECH is considered a large-cap stock.
G/PE Ratio
0.87
0.87
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
25.61
25.61
The estimated PE is for the year 2028.
LT Growth
21.68%
21.68%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
0.49%
0.49%
The twelve month estimated dividend yield represents 12.59% of earnings forecasts.
Beta
161
161
For 1% of index variation, the stock varies on average by 1.61%.
Correlation
0.53
0.53
52.70% of stock movements are explained by index variations.
Value at Risk
43.41
43.41
The value at risk is estimated at EUR 43.41. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.01.2002
02.01.2002